What are Carbonic Anhydrase Inhibitors?

Carbonic anhydrase inhibitors (CAIs) are a class of medications that block the enzyme carbonic anhydrase. This enzyme is responsible for converting carbon dioxide and water into carbonic acid, a reaction crucial for fluid balance and acid-base regulation in the body. The most well-known CAI is acetazolamide, which has been used for decades to treat conditions such as glaucoma, epilepsy, and altitude sickness. Recent research has explored its efficacy for vertigo and other inner ear disorders.

Mechanism of Action in Vertigo

In the inner ear, carbonic anhydrase helps regulate the production and pH of endolymph, the fluid that fills the vestibular labyrinth. Overproduction or abnormal composition of endolymph can lead to vertigo attacks, as seen in Meniere's disease. By inhibiting carbonic anhydrase, acetazolamide reduces endolymph production, thereby decreasing pressure and fluid buildup. This mechanism is thought to stabilize the vestibular system and prevent the onset of spinning sensations.

Evidence and Clinical Use

Clinical studies have shown that acetazolamide can reduce the frequency and severity of vertigo episodes in patients with Meniere's disease. It is often prescribed as a second-line treatment when standard diuretics or lifestyle modifications fail. Doses typically range from 250 mg to 500 mg per day, and side effects may include tingling in the limbs, metallic taste, and electrolyte imbalances. Long-term use requires monitoring of kidney function and blood electrolytes.

Considerations and Future Directions

While acetazolamide is not a cure for vertigo, it offers a valuable option for symptom control. Ongoing research is investigating other carbonic anhydrase inhibitors, such as methazolamide, for their potential benefits. Patients should always consult with an otolaryngologist or neurologist before starting acetazolamide, as it may interact with other medications or exacerbate certain medical conditions.